Xiao Wang, MD
he/him/his
Clinical FellowAbout
Research
Publications
2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
Nassar AH, Bou Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske EP, Babu P, Choueiri TK, Rakaee M, Busund LR, Takabe Y, Lau SF, Rall K, Naqash AR, Jansen C, Wang X, Challa P, Tarantino P, Partridge AH, Tolaney SM, Kwiatkowski DJ, Winer EP. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. J Natl Cancer Inst 2025 PMID: 41418409, DOI: 10.1093/jnci/djaf344.Peer-Reviewed Original ResearchMolecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.
Wang X, Lee D, Yang S, Li Y, Soulos P, Gross C, Wang S, Chiang A. Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2025, 1-7. PMID: 41072474, DOI: 10.6004/jnccn.2025.7063.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerLong test turnaround timesNon-small cell lung cancerCell lung cancerRetrospective cohort studyTest turnaround timeNext-generation sequencingTargeted therapyClinical outcomesAssociated with worse median progression-free survivalLung cancerUS patientsElectronic health record-derivedMedian progression-free survivalRetrospective cohort study of patientsNontarget treatmentCohort study of patientsProgression-free survivalTargetable genomic alterationsFirst-line treatmentHistory of smokingStudy of patientsNGS useEGFR testingNontargeted therapiesAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original Research
2024
Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions
Wang X, Arya S, Patel S, Saw S, Decena M, Hirsh R, Pegues D, Ziegler M. Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions. Infection Control And Hospital Epidemiology 2024, 45: 1168-1175. PMID: 39087709, PMCID: PMC11611503, DOI: 10.1017/ice.2024.103.Peer-Reviewed Original ResearchSociety for Healthcare EpidemiologyNeutrophil recoverySociety for Healthcare Epidemiology of America Research NetworkFever managementHealthcare institutionsManagement of neutropenic feverFever management practicesFirst-line therapyBone marrow transplantationFirst-line treatmentAntipseudomonal antibioticsNeutropenic feverAntimicrobial prophylaxisMarrow transplantationTreatment courseAntibiotic practicesElectronic surveySupportive careDe-EscalationResearch NetworkInstitutional guidelinesSurvey studyRobust evidenceProphylaxisResponding institutionsBig Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.
Wang X, Chiang A. Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives. American Society Of Clinical Oncology Educational Book 2024, 44: e432520. PMID: 38830134, DOI: 10.1200/edbk_432520.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSmall cell lung cancerCell lung cancerLung cancerSystemic therapyHigh-grade neuroendocrine carcinomaAssociated with tobacco useIntracranial radiotherapySCLC treatmentChemosensitive diseaseNeuroendocrine carcinomaTargeted therapyPatientsCancerTherapyTobacco usePsychosocial burdenDiseasePatient perspectiveRadiotherapyImmunotherapyCarcinomaRelapseThoracicLungClinic
2023
Association of early antibiotic de-escalation with length of stay in patients with myeloid neoplasms and neutropenic fever.
Wang X, Arya S, Decena M, Powers J, Landsburg D, Hirsh R, Ziegler M. Association of early antibiotic de-escalation with length of stay in patients with myeloid neoplasms and neutropenic fever. JCO Oncology Practice 2023, 19: 425-425. DOI: 10.1200/op.2023.19.11_suppl.425.Peer-Reviewed Original ResearchLength of stayDe-escalated patientsAntibiotic de-escalationNeutropenic feverNeutrophil recoveryDe-EscalationMyeloid neoplasmsIV antibioticsRetrospective analysisSafety of de-escalationHospital daysIntravenous (IV) antibioticsIntensity of chemotherapyMyeloid neoplasm patientsPositive bacterial culturesAssociated with lower LOSCharlson Comorbidity IndexClinically significant reductionLower length of stayChemotherapy groupChart reviewClinical outcomesClinical complicationsManual chart reviewMultivariate linear regressionClinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma
Marmarelis M, Wang X, Roshkovan L, Grady C, Miura J, Ginsberg M, Ciunci C, Egger J, Walker S, Cercek A, Foote M, Litzky L, Nash G, Haas A, Karakousis G, Cengel K, Katz S, Zauderer M, Langer C, Offin M. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open 2023, 6: e232526. PMID: 36897589, PMCID: PMC10942662, DOI: 10.1001/jamanetworkopen.2023.2526.Peer-Reviewed Original ResearchConceptsDiffuse malignant peritoneal mesotheliomaMedian progression-free survivalProgression-free survivalMalignant peritoneal mesotheliomaMedian OSPembrolizumab monotherapyEpithelioid histologyPartial responsePD-L1Nonepithelioid histologyOverall survivalPeritoneal mesotheliomaPositive tumor PD-L1 expressionTertiary care academic cancer centerCohort studyAssociation of disease characteristicsInitiation of pembrolizumab monotherapyTumor PD-L1 expressionProgrammed death-ligand 1Dual-center cohort studyPD-L1 positivityMedian overall survivalPartial response ratePD-L1 expressionPD-L1 statusA Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Iams W, Balbach M, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis M, Sethakorn N, Leal T, Sackstein P, Kim C, Robinson M, Mehta K, Hsu R, Nieva J, Patil T, Camidge D. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer 2023, 24: 228-234. PMID: 36841727, PMCID: PMC10234144, DOI: 10.1016/j.cllc.2023.01.009.Peer-Reviewed Original ResearchConceptsMutant non-small cell lung cancerNon-small cell lung cancerMulticenter retrospective chart reviewCell lung cancerClinical outcomesFood and Drug AdministrationStage IVMedian OSPD-(L)1Second-lineOverall survivalSystemic therapySTK11 mutationsKRAS G12C mutated non-small cell lung cancerLung cancerPatient populationFDA-approved targeted therapyPD-(L)1 inhibitor monotherapyRetrospective chart review of patientsSecond-line systemic therapyFirst-line systemic therapyChart review of patientsReview of clinical outcomesDocetaxel-containing regimensDocetaxel-treated patients
2022
A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma
Wang X, Katz S, Miura J, Karakousis G, Roshkovan L, Walker S, McNulty S, Ciunci C, Cengel K, Langer C, Marmarelis M. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLOS ONE 2022, 17: e0275187. PMID: 36174024, PMCID: PMC9521908, DOI: 10.1371/journal.pone.0275187.Peer-Reviewed Original ResearchConceptsDiffuse malignant peritoneal mesotheliomaMedian overall survivalHyperthermic intraperitoneal chemotherapySingle-center retrospective cohort studyMalignant peritoneal mesotheliomaNeoadjuvant chemotherapyCytoreductive surgeryRetrospective cohort studySystemic chemotherapyAdjuvant chemotherapyNeoadjuvant patientsOverall survivalPeritoneal mesotheliomaAssociated with worse median overall survivalDMPM patientsCohort studyEstimated median overall survivalHazard ratioAssociated with worse outcomesPerioperative systemic chemotherapyOutcomes of patientsKaplan-Meier curvesCox proportional hazards modelsPre-operative periodMalignant mesothelioma casesSevere aplastic anaemia after serial vaccinations for SARS‐CoV‐2, pneumococcus and seasonal influenza
Wang X, Laczko D, Caponetti G, Rabatin S, Babushok D. Severe aplastic anaemia after serial vaccinations for SARS‐CoV‐2, pneumococcus and seasonal influenza. EJHaem 2022, 3: 983-988. PMID: 35941884, PMCID: PMC9348402, DOI: 10.1002/jha2.443.Peer-Reviewed Case Reports and Technical NotesSevere aplastic anemiaAplastic anemiaDevelopment of severe aplastic anemiaSARS-CoV-2MRNA SARS-CoV-2 vaccineSARS-CoV-2 vaccinesProgressive pancytopeniaInfluenza vaccineSeasonal influenzaProgressive symptomsRespiratory syndrome coronavirus 2Vaccine exposureSyndrome coronavirus 2Vaccine sequenceVaccineInfluenzaAnemiaVaccination effortsCoronavirus 2Coronavirus diseasePancytopeniaPneumococcal
Academic Achievements & Community Involvement
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
333 Cedar Street
New Haven, Connecticut 06510
United States